HUE042449T2 - Új 4-metoxi-pirrolszármazékok vagy sóik és az azokat tartalmazó gyógyászati készítmények - Google Patents

Új 4-metoxi-pirrolszármazékok vagy sóik és az azokat tartalmazó gyógyászati készítmények

Info

Publication number
HUE042449T2
HUE042449T2 HUE16786741A HUE16786741A HUE042449T2 HU E042449 T2 HUE042449 T2 HU E042449T2 HU E16786741 A HUE16786741 A HU E16786741A HU E16786741 A HUE16786741 A HU E16786741A HU E042449 T2 HUE042449 T2 HU E042449T2
Authority
HU
Hungary
Prior art keywords
salts
novel
pharmaceutical composition
same
pyrrole derivatives
Prior art date
Application number
HUE16786741A
Other languages
English (en)
Inventor
Chun Ho Lee
Seung Chul Lee
Yeon Im Lee
Deok Ki Eom
Mi Ryeong Han
Eun Ji Koh
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of HUE042449T2 publication Critical patent/HUE042449T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
HUE16786741A 2015-04-27 2016-04-27 Új 4-metoxi-pirrolszármazékok vagy sóik és az azokat tartalmazó gyógyászati készítmények HUE042449T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150058712 2015-04-27
KR1020160013588A KR101613245B1 (ko) 2015-04-27 2016-02-03 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
HUE042449T2 true HUE042449T2 (hu) 2019-06-28

Family

ID=55916928

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16786741A HUE042449T2 (hu) 2015-04-27 2016-04-27 Új 4-metoxi-pirrolszármazékok vagy sóik és az azokat tartalmazó gyógyászati készítmények

Country Status (29)

Country Link
US (1) US10100010B1 (hu)
EP (1) EP3197867B1 (hu)
JP (1) JP6244498B1 (hu)
KR (2) KR101613245B1 (hu)
CN (1) CN107001263B (hu)
AU (1) AU2016255308B2 (hu)
CA (1) CA2977750C (hu)
CL (1) CL2017002571A1 (hu)
CO (1) CO2017010539A2 (hu)
DO (2) DOP2017000230A (hu)
EC (1) ECSP17071036A (hu)
ES (1) ES2703709T3 (hu)
HR (1) HRP20182066T1 (hu)
HU (1) HUE042449T2 (hu)
MA (1) MA40887B1 (hu)
MX (1) MX2017012507A (hu)
MY (1) MY193257A (hu)
NZ (1) NZ734896A (hu)
PE (1) PE20180022A1 (hu)
PH (1) PH12017501755A1 (hu)
PL (1) PL3197867T3 (hu)
PT (1) PT3197867T (hu)
RS (1) RS58076B1 (hu)
RU (1) RU2663895C1 (hu)
SA (1) SA517390127B1 (hu)
SG (1) SG11201706877RA (hu)
SI (1) SI3197867T1 (hu)
TN (1) TN2017000424A1 (hu)
WO (1) WO2016175555A2 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017164575A1 (en) * 2016-03-25 2017-09-28 Daewoong Pharmaceutical Co.,Ltd. Novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine
KR102081920B1 (ko) * 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR20170113040A (ko) * 2016-03-25 2017-10-12 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염
KR102233456B1 (ko) * 2017-05-31 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102233455B1 (ko) * 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
WO2020060213A1 (ko) 2018-09-19 2020-03-26 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
KR102126576B1 (ko) * 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
WO2021125874A1 (ko) 2019-12-18 2021-06-24 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루우로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 액상 약학적 조성물
JP7404561B2 (ja) * 2020-06-17 2023-12-25 イルドン ファーマシューティカル カンパニー リミテッド 新規な酸分泌抑制剤及びその用途
WO2022051979A1 (zh) * 2020-09-10 2022-03-17 广东莱佛士制药技术有限公司 一种制备钾离子竞争性阻滞剂中间体的方法
CN112094219B (zh) * 2020-09-10 2022-08-05 广东莱佛士制药技术有限公司 一种制备钾离子竞争性阻滞剂中间体的方法
TW202241409A (zh) 2020-12-18 2022-11-01 南韓商大熊製藥股份有限公司 包含1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺之用於經口投予的新調配物
BR112023024578A2 (pt) 2021-05-26 2024-02-06 Daewoong Pharmaceutical Co Ltd “formulação para injeção compreendendo o composto 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina ou um sal farmaceuticamente aceitável do mesmo, uma ciclodextrina e um agente isotonizante, bem como uso terapêutico do referido composto
BR112023024653A2 (pt) 2021-05-26 2024-02-27 Daewoong Pharmaceutical Co Ltd Recipiente de fármaco compreendendo composição farmacêutica líquida de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metóxi-1h-pirrol-3-il)-n-metilmetanamina
KR102556500B1 (ko) * 2021-11-19 2023-07-19 하나제약 주식회사 피롤 유도체 또는 이의 약학적 또는 식품학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 위장 질환의 예방, 개선 또는 치료용 조성물
WO2023113487A1 (ko) * 2021-12-15 2023-06-22 주식회사 대웅제약 펙수프라잔 주사제 조성물 용법용량
KR20230091056A (ko) * 2021-12-15 2023-06-22 일동제약(주) 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
WO2023113474A1 (ko) * 2021-12-15 2023-06-22 일동제약(주) 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
KR20230102353A (ko) * 2021-12-30 2023-07-07 주식회사 대웅제약 삼중음성유방암의 예방 또는 치료용 약학적 조성물
WO2023211843A1 (en) * 2022-04-25 2023-11-02 Daewoong Pharmaceutical Co., Ltd. Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions
WO2023229323A1 (ko) * 2022-05-23 2023-11-30 일동제약(주) 6-메톡시피리딘-3-일 유도체의 제조방법
WO2023229322A1 (ko) * 2022-05-23 2023-11-30 일동제약(주) 6-메톡시피리딘-3-일 유도체의 제조방법
CN117820193A (zh) * 2022-09-29 2024-04-05 安徽皓元药业有限公司 一种非苏拉赞盐酸盐晶型a及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511613A (ja) 2001-11-08 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 疾患治療用アザビシクロ置換ヘテロアリール化合物
US7186716B2 (en) 2002-08-12 2007-03-06 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
JP4942654B2 (ja) 2004-08-23 2012-05-30 イーライ リリー アンド カンパニー ヒスタミンh3受容体薬剤、製剤及び治療的使用
KR100958830B1 (ko) 2004-09-03 2010-05-24 주식회사유한양행 피롤로[2,3-c]피리딘 유도체 및 그의 제조방법
JP5173192B2 (ja) * 2004-09-30 2013-03-27 武田薬品工業株式会社 プロトンポンプ阻害薬
ES2359725T3 (es) 2004-09-30 2011-05-26 F. Hoffmann-La Roche Ag Composiciones y métodos para el tratamiento de trastornos cognitivos.
US7977488B2 (en) * 2005-08-30 2011-07-12 Takeda Pharmaceutical Company Limited 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
DE102005041246A1 (de) 2005-08-31 2007-03-08 Basf Coatings Ag Von Molybän- und Wolframverbindungen freie, Cäsiumverbindungen enthaltende, härtbare Gemische auf der Basis blockierter Polyisocyanate, Verfahren zu ihrer Herstellung und ihre Verwendung
CN101341149B (zh) 2005-12-19 2011-06-08 拉夸里亚创药株式会社 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途
EP2023909B1 (en) 2006-05-04 2009-11-18 Solvay Pharmaceuticals B.V. Muscarinic agonists to treat impulse control disorders
DE102006027229A1 (de) * 2006-06-09 2007-12-20 Grünenthal GmbH 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
WO2008131779A1 (en) 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
JP5894574B2 (ja) 2010-04-22 2016-03-30 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
BR112015010908A2 (pt) 2012-11-19 2017-07-11 Jiangsu Hansoh Pharmaceutical Co Ltd derivado de pirrol sulfonamida, método de preparação para o mesmo e aplicação médica do mesmo
CN105120865A (zh) 2013-03-15 2015-12-02 阿卡蒂亚药品公司 蕈毒碱激动剂
ITBS20130175A1 (it) 2013-11-22 2015-05-23 Ind Saleri Italo Spa Gruppo pompa di raffreddamento regolabile con girante regolabile
US10040780B2 (en) 2014-03-03 2018-08-07 The Regents Of The University Of California Mcl-1 antagonists
CN104447191B (zh) 2014-10-30 2016-03-23 绵阳达高特新材料有限公司 4-溴-1,2-二氢环丁烯并[α]萘化合物及其制备方法
CN104447491B (zh) * 2014-11-19 2017-06-23 连云港恒运医药有限公司 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途

Also Published As

Publication number Publication date
PH12017501755A1 (en) 2018-04-02
CN107001263B (zh) 2018-10-19
ES2703709T3 (es) 2019-03-12
NZ734896A (en) 2019-07-26
CO2017010539A2 (es) 2018-01-31
DOP2021000213A (es) 2021-11-15
EP3197867B1 (en) 2018-11-14
AU2016255308B2 (en) 2017-08-31
EP3197867A2 (en) 2017-08-02
BR112017020056A2 (pt) 2018-06-05
CN107001263A (zh) 2017-08-01
MA40887A (fr) 2017-08-02
MX2017012507A (es) 2018-01-30
KR20160127646A (ko) 2016-11-04
CL2017002571A1 (es) 2018-03-16
KR101613245B1 (ko) 2016-04-18
JP2017538716A (ja) 2017-12-28
SG11201706877RA (en) 2017-09-28
PT3197867T (pt) 2019-01-10
US10100010B1 (en) 2018-10-16
AU2016255308A1 (en) 2017-05-18
CA2977750A1 (en) 2016-11-03
WO2016175555A2 (en) 2016-11-03
KR101818704B1 (ko) 2018-02-21
MA40887B1 (fr) 2019-01-31
PE20180022A1 (es) 2018-01-09
WO2016175555A3 (en) 2017-02-16
RS58076B1 (sr) 2019-02-28
CA2977750C (en) 2019-06-11
HRP20182066T1 (hr) 2019-02-08
DOP2017000230A (es) 2017-10-31
RU2663895C1 (ru) 2018-08-13
WO2016175555A8 (en) 2017-09-08
JP6244498B1 (ja) 2017-12-06
PL3197867T3 (pl) 2019-03-29
ECSP17071036A (es) 2017-12-01
SA517390127B1 (ar) 2020-11-08
SI3197867T1 (sl) 2019-02-28
MY193257A (en) 2022-09-28
TN2017000424A1 (en) 2019-04-12
EP3197867A4 (en) 2017-09-06

Similar Documents

Publication Publication Date Title
HRP20182066T1 (hr) Novi derivati 4-metoksi pirola ili njihove soli i farmaceutski pripravak koji ih sadrži
IL265360B (en) Pharmaceutical composition
IL265260B (en) pharmaceutical preparations
IL269061A (en) A pharmaceutical preparation containing Selexifag
IL271986A (en) pharmaceutical preparation
IL253538B (en) Heterocyclic compound and pharmaceutical compound containing it
IL262654A (en) Pharmacy preparation
HK1256674A1 (zh) 氘修飾的brigatinib衍生物、含有該化合物的藥物組合物及其用途
IL265349A (en) Pharmaceutical composition
GB201712159D0 (en) Pharmaceutical composition
IL263040A (en) Pharmaceutical composition comprising eteplirsen
EP2989093A4 (en) Novel triazole derivatives or salts thereof and pharmaceutical composition therefor
EP3328368A4 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM
GB201719447D0 (en) Pharmaceutical composition
IL272419A (en) Pharmaceutical composition
EP3448839A4 (en) CHINAZOLINE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION THEREWITH
IL257621B (en) A catechol derivative and a pharmaceutical preparation that includes it
GB201615917D0 (en) Pharmaceutical composition
EP3727485C0 (en) PHARMACEUTICAL COMPOSITION
GB201615914D0 (en) Pharmaceutical composition
GB201615910D0 (en) Pharmaceutical composition
PL3262047T3 (pl) Pochodne imidazopirymidyny i imidazotriazyny i kompozycje farmaceutyczne je zawierające
IL265436B (en) Pharmacy preparation
HUE057830T2 (hu) Famitinib tartalmú gyógyszerkészítmény
IL265428A (en) Pharmaceutical composition